TY - JOUR
T1 - Sex-Specific Association of Myocardial Fibrosis with Mortality in Patients with Aortic Stenosis
AU - Kwak, Soongu
AU - Singh, Anvesha
AU - Everett, Russell J.
AU - Treibel, Thomas A.
AU - Lim, Jaehyun
AU - Won, Sungho
AU - Williams, Michelle C.
AU - Loganathan, Krithika
AU - Bing, Rong
AU - Craig, Neil
AU - Singh, Trisha
AU - Joshi, Shruti
AU - Lee, Heesun
AU - Lee, Whal
AU - Kim, Yong Jin
AU - Chin, Calvin W.L.
AU - Fukui, Miho
AU - Al Musa, Tarique
AU - Rigolli, Marzia
AU - Tastet, Lionel
AU - Dobson, Laura E.
AU - Wiesemann, Stephanie
AU - Ferreira, Vanessa M.
AU - Captur, Gabriella
AU - Lee, Sahmin
AU - Schulz-Menger, Jeanette
AU - Schelbert, Erik B.
AU - Clavel, Marie Annick
AU - Park, Sung Ji
AU - Pellegrini, Costanza
AU - Hadamitzky, Martin
AU - Gerber, Bernhard L.
AU - Newby, David E.
AU - Myerson, Saul G.
AU - Pibarot, Phillipe
AU - Cavalcante, João L.
AU - McCann, Gerry P.
AU - Greenwood, John P.
AU - Moon, James C.
AU - Dweck, Marc R.
AU - Lee, Seung Pyo
N1 - Publisher Copyright:
© 2025 American Medical Association.
PY - 2025
Y1 - 2025
N2 - Importance: Myocardial fibrosis in aortic stenosis (AS) may exhibit sex differences. However, its prognostic significance in women with AS remains unclear. Objective: To investigate sex differences in myocardial fibrosis assessed by cardiovascular magnetic resonance (CMR) and evaluate its prognostic value in women and men with AS. Design, Setting, and Participants: Patients with severe AS who underwent CMR before aortic valve replacement (AVR) were prospectively enrolled from 13 international sites between March 2011 and September 2021. Myocardial fibrosis was evaluated using extracellular volume fraction (ECV%) and late gadolinium enhancement (LGE). The main analysis was conducted on patients without obstructive coronary artery disease (CAD), defined as those with no history of myocardial infarction and no concomitant coronary artery bypass grafting. Data were analyzed from December 2023 to February 2024. Exposures: Surgical or transcatheter AVR. Main Outcomes and Measures: The primary outcome was post-AVR all-cause mortality and the secondary outcome was cardiovascular mortality. Results: Of 822 patients, 670 were without obstructive CAD (368 men [55%] and 302 women [45%]). Among these, women and men had a similar age (median, 72 years vs 71 years, respectively), comorbidities, and AS severity. ECV% was similar between sexes; however, women had less LGE (both infarct and noninfarct LGE). After a median follow-up of 3.7 (IQR, 2.1-4.7) years, there were 76 deaths (11.3%), including 29 adjudicated cardiovascular deaths, in patients without obstructive CAD. Increasing ECV% and LGE were associated with higher all-cause and cardiovascular mortality in both sexes. Cox analyses demonstrated that both ECV% and LGE were associated with higher all-cause mortality without significant interaction by sex (women: adjusted hazard ratio [HR], 1.08 per 1% ECV% increase; 95% CI, 1.04-1.12; P <.001; men: adjusted HR, 1.01; 95% CI, 0.96-1.06; P =.66; P for interaction by sex =.09 and women: adjusted HR, 2.49 for the presence of LGE; 95% CI, 1.07-5.80; P =.03; men: adjusted HR, 1.82; 95% CI, 1.00-3.32; P =.04; P for interaction by sex =.68). In the entire population (n = 822), both noninfarct and infarct-related LGE were associated with increased mortality without significant interaction by sex. Conclusions and Relevance: In this study, patients with severe AS who underwent AVR exhibited similar ECV% between sexes, while women had lower LGE. Increased myocardial fibrosis provided important prognostic value for both sexes.
AB - Importance: Myocardial fibrosis in aortic stenosis (AS) may exhibit sex differences. However, its prognostic significance in women with AS remains unclear. Objective: To investigate sex differences in myocardial fibrosis assessed by cardiovascular magnetic resonance (CMR) and evaluate its prognostic value in women and men with AS. Design, Setting, and Participants: Patients with severe AS who underwent CMR before aortic valve replacement (AVR) were prospectively enrolled from 13 international sites between March 2011 and September 2021. Myocardial fibrosis was evaluated using extracellular volume fraction (ECV%) and late gadolinium enhancement (LGE). The main analysis was conducted on patients without obstructive coronary artery disease (CAD), defined as those with no history of myocardial infarction and no concomitant coronary artery bypass grafting. Data were analyzed from December 2023 to February 2024. Exposures: Surgical or transcatheter AVR. Main Outcomes and Measures: The primary outcome was post-AVR all-cause mortality and the secondary outcome was cardiovascular mortality. Results: Of 822 patients, 670 were without obstructive CAD (368 men [55%] and 302 women [45%]). Among these, women and men had a similar age (median, 72 years vs 71 years, respectively), comorbidities, and AS severity. ECV% was similar between sexes; however, women had less LGE (both infarct and noninfarct LGE). After a median follow-up of 3.7 (IQR, 2.1-4.7) years, there were 76 deaths (11.3%), including 29 adjudicated cardiovascular deaths, in patients without obstructive CAD. Increasing ECV% and LGE were associated with higher all-cause and cardiovascular mortality in both sexes. Cox analyses demonstrated that both ECV% and LGE were associated with higher all-cause mortality without significant interaction by sex (women: adjusted hazard ratio [HR], 1.08 per 1% ECV% increase; 95% CI, 1.04-1.12; P <.001; men: adjusted HR, 1.01; 95% CI, 0.96-1.06; P =.66; P for interaction by sex =.09 and women: adjusted HR, 2.49 for the presence of LGE; 95% CI, 1.07-5.80; P =.03; men: adjusted HR, 1.82; 95% CI, 1.00-3.32; P =.04; P for interaction by sex =.68). In the entire population (n = 822), both noninfarct and infarct-related LGE were associated with increased mortality without significant interaction by sex. Conclusions and Relevance: In this study, patients with severe AS who underwent AVR exhibited similar ECV% between sexes, while women had lower LGE. Increased myocardial fibrosis provided important prognostic value for both sexes.
UR - http://www.scopus.com/inward/record.url?scp=86000130480&partnerID=8YFLogxK
U2 - 10.1001/jamacardio.2024.5593
DO - 10.1001/jamacardio.2024.5593
M3 - Article
C2 - 39969863
AN - SCOPUS:86000130480
SN - 2380-6583
JO - JAMA Cardiology
JF - JAMA Cardiology
ER -